NEWARK, Calif.--(BUSINESS WIRE)--Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, and Navinci Diagnostics, leader of innovative in situ proximity ligation ...

The new kit combines Vector’s validated lectins with Navinci’s in situ PLA technology to gain insights beyond protein expression The Glysite™ Explorer in situ PLA Glycan Detection Kit is a fully ...

Vector Laboratories has completed a $124 million cash buyout backed by Thompson Street Capital Partners and will begin an acquisition strategy to expand protein detection capabilities. Vector ...

GTCR, a leading private equity firm, today announced that it has completed a strategic equity investment in Vector Laboratories, Inc. (“Vector” or the “Company”), through GTCR’s previously established ...

Accomplished marketing leader to drive strategic growth and customer-first initiatives NEWARK, Calif. — Vector Laboratories, a manufacturing partner of reagents and critical components for the ...

This project builds on recent work reporting tick transmission of relapsing fever spirochetes and genome sequencing of both the pathogen and tick vector. We have utilized both next generation and ...

Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, announced ...

Vector Acquisition Corporation (Nasdaq: VACQ) (“Vector”), a publicly traded special purpose acquisition company backed by leading technology investor Vector Capital, today announced that Vector’s ...

LONG BEACH, Calif.--(BUSINESS WIRE)--Vector Acquisition Corporation (Nasdaq: VACQ) (“Vector”), a publicly traded special purpose acquisition company backed by leading technology investor Vector ...

NEWARK, Calif.--(BUSINESS WIRE)--Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and ...